Lineage Cell Therapeutics, Inc.
LCTXNYSEAMERICANHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $260.66M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.88$2.09
- Volume (live)
- -
- Avg. volume (3M)
- 1.60M
Lineage Cell Therapeutics (LCTX) Stock Price & Financial Analysis
Lineage Cell Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.97 - $1.01 |
|---|---|
| 52-Week High | $2.09 |
| 52-Week Low | $0.88 |
| Open | $0.99 |
| Volume (last close) | 1.91M |
| Average Volume (3M) | 1.60M |
| Revenue (TTM) | 13.08M |
|---|---|
| Net Income (TTM) | -32.26M |
| Free Cash Flow (TTM) | -24.10M |
| EPS (TTM) | −$0.13 |
| Profit Margin | -246.58% |
| Operating Margin | -205.23% |
| Return on Equity (ROE) | -52.96% |
| Debt to Equity | 0.04 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Last Dividend Ex-Date | Dec 15, 2003 |
| Market Cap | 260.66M |
|---|---|
| Shares Outstanding | 261.47M |
| Price to Sales (P/S) | 19.92 |
| Price to Book (P/B) | 4.28 |
| EV/EBITDA | -4.72 |
| 50-Day MA | $1.03 |
|---|---|
| 200-Day MA | $1.36 |
| 1-Year Change | −39.57% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Lineage Cell Therapeutics at a Glance
As of the Oct 26, 2026 close, Lineage Cell Therapeutics (LCTX) has a market capitalization of $260.66M. The stock trades at 19.9× sales. Over the trailing twelve months it lost $32.26M on revenue of $13.08M and burned $24.10M of free cash flow. Revenue grew 19.9% year over year.
As of its latest reported balance sheet, it holds $37.35M in cash and securities against $2.30M of debt, a net cash position of $35.06M.
Lineage Cell Therapeutics does not currently pay a dividend.
The share price is down 39.6% over the past year. At $1.00 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $0.88 to $2.09, below its 200-day moving average of $1.36.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $6.25, 526.9% above the Oct 26, 2026 close.
Frequently Asked Questions About Lineage Cell Therapeutics
What is the current stock price for LCTX?
As of the Oct 26, 2026 close, LCTX stock trades at $1.00. The 52-week range is $0.88–$2.09, with a day range of $0.97–$1.00.
What is the P/E ratio for LCTX?
The P/E ratio (Price-to-Earnings) for LCTX is shown in the Key Statistics section. This valuation metric helps compare Lineage Cell Therapeutics, Inc. to industry peers.
Does LCTX pay dividends?
Lineage Cell Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for LCTX?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for LCTX is Buy. The average 12-month price target is $6.25, a 526.9% upside from the Oct 26, 2026 close of $1.00.
What is the market cap of LCTX?
As of the Oct 26, 2026 close, Lineage Cell Therapeutics's market capitalization is $260.7M, classifying it as a micro-cap company. Lineage Cell Therapeutics operates in the Healthcare sector within the Biotechnology industry.